ELISA demonstrating the specificity of HCA209 using various antigens as coating reagents. Antigens were coated at 5 µg/mL on a microtiter plate overnight. After washing and blocking with 5% BSA, the anti-Ustekinumab antibody HCA209 (AbD18334; 20µL from a 2µg/mL solution) was added followed by an anti-His-tag antibody conjugated to HRP in HiSPEC buffer (BUF049). Detection was performed using QuantaBlu™ fluorogenic peroxidase substrate
Inhibition of Ustekinumab binding to IL-23 by HCA209. IL-23 (1.0 µg/mL) was used as the coating antigen followed by a pre-incubated mixture of the anti-idiotypic antibody HCA209 titrated into a constant amount of Ustekinumab (0.3 µg/mL). Free Ustekinumab still capable of binding to the plate was detected using Mouse anti Human IgG(Fc):HRP (MCA647P). Data is shown as the mean of three measurements
HCA209 PK assay - bridging format. Anti-Ustekinumab antibody HCA209 (AbD18334) was coated at 1.0 µg/mL on a microtiter plate overnight. After washing and blocking with 5% BSA in PBST, Ustekinumab spiked into 10% human serum was added. Detection was performed by adding HRP conjugated anti-Ustekinumab antibody (HCA210), 2 µg/mL in HiSPEC buffer (BUF049), plus QuantaBlu™ fluorogenic peroxidase substrate. Data is shown as the mean of three measurements
Anti-ustekinumab antibody is a recombinant, neutralizing, high affinity anti-idiotypic antibody in monovalent Fab format, ideal for bioanalytical assay development for ustekinumab and biosimilars. It is recommended as capture antibody in PK bridging ELISA format with HCA210/HCA210P for detection.
HuCAL Fab monovalent
1 Formats Available
Negative Isotype Controls
Ustekinumab (branded as Stelara®) is a fully human monoclonal antibody drug (IgG1/kappa) that has been approved for treatment of moderate to severe psoriasis. Ustekinumab is also being investigated for the treatment of psoriatic arthritis, for multiple sclerosis and sarcoidosis. Studies indicate that it may also have potential for treating severe Crohns disease. Ustekinumab is directed against the p40 subunit of interleukin-12 and interleukin-23 and acts by blocking the binding of these two cytokines to, and preventing activation of, T-lymphocytes.
Clone 18334 is an anti-idiotypic antibody that specifically recognises the Ustekinumab monoclonal antibody and inhibits the binding of Ustekinumab to its target. It can be used to measure Ustekinumab levels in serum from patients.
Clone 18334 is an ultra-high affinity anti idiotypic antibody.The monovalent intrinsic affinity of this antibody was measured as KD=0.4 nM by real time, label-free molecular interaction analysis using an Attana A200 instrument on immobilized Ustekinumab.
For our full range of Ustekinumab antibodies, please visit our website.
A monovalent human recombinant Fab selected from the HuCAL® phage display library, expressed in E. coli. The antibody is tagged with a DYKDDDDK tag and a HIS-tag (HHHHHH) at the C-terminus of the antibody heavy chain.
Approx. Protein Concentrations
Antibody concentration 0.5 mg/ml.
Reagents In The Kit
Preparing The Antibody
Phosphate buffered saline.
Store at +4oC or at -20oC if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
12 months from date of despatch.
Sold under license of U.S. Patents 6,300,064, 6,696,248, 6,708,484, 6,753,136, European Patent 0,859,841 and corresponding patents.This antibody was developed by Bio-Rad, a wholly owned subsidiary of Bio-Rad Laboratories Inc., Zeppelinstr. 4, 82178 Puchheim, Germany.Stelara is a registered trademark of Centocor.
For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
For research purposes only
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.